Clinical and biochemical consequences of P450 oxidoreductase deficiency

Endocrine Development

Volumn 20, Issue , 2010, Pages 63-79

  Flück, Christa E ^a   Pandey, Amit V ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; CYTOCHROME P450 REDUCTASE; DRUG METABOLIZING ENZYME; ESTRIOL; TESTOSTERONE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ANDROGEN SYNTHESIS; AROMATIZATION; ARTICLE; ELECTRON TRANSPORT; ENZYME ACTIVITY; HUMAN; KARYOTYPE 46,XY; MISSENSE MUTATION; P450 OXIDOREDUCTASE DEFICIENCY; PREGNANCY; PRIORITY JOURNAL; SEXUAL DEVELOPMENT; SKELETON MALFORMATION; STEROIDOGENESIS;

ANTLEY-BIXLER SYNDROME PHENOTYPE; BIOCHEMISTRY; BONE DEVELOPMENT; ELECTRON TRANSPORT; FEMALE; HUMANS; INFANT, NEWBORN; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; PREGNANCY;

EID: 78751537714     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000321221     Document Type: Article

References (70)

1. Lu AY, Junk KW, Coon MJ: Resolution of the cytochrome P-450-containing β-hydroxylation system of liver microsomes into three components. J Biol Chem 1969;244:3714-3721.
2. Yamano S, Aoyama T, McBride OW, Hardwick JP, Gelboin HV, Gonzalez FJ: Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7. Mol Pharmacol 1989;36:83-88.
3. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL: Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:2318-2322.
4. Wang M, Roberts DL, Paschke R, Shea TM, Masters BSS, Kim JJ: Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN-and FAD-containing enzymes. Proc Natl Acad Sci USA 1997;94:8411-8416.
5. Miller WL: Regulation of steroidogenesis by electron transfer. Endocrinology 2005;146:2544-2550.
6. Guengerich FP, Johnson WW: Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. Biochemistry 1997;36:14741-14750.
7. Auchus RJ, Lee TC, Miller WL: Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273:3158-3165.
8. Yamazaki H, Nakano M, Imai Y, Ueng YF, Guengerich FP, Shimada T: Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 1996;325: 174-182.
9. Loughran PA, Roman LJ, Miller RT, Masters BS: The kinetic and spectral characterization of the E. coli-expressed mammalian CYP4A7: cytochrome b5 effects vary with substrate. Arch Biochem Biophys 2001;385:311-321.
10. Yanagibashi K, Hall PF: Role of electron transport in the regulation of the lyase activity of C21 sidechain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 1986;261: 8429-8433.
11. Lin D, Black SM, Nagahama Y, Miller WL: Steroid 17α-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine-106 and P450 reductase. Endocrinology 1993;132:2498-2506.
12. Grumbach MM, Auchus RJ: Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999;84:4677-4694.
13. Auchus RJ: The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432-438.
14. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, Ogata T: Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006;91:2643-2649.
15. Shackleton C, Marcos J, Arlt W, Hauffa BP: Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet 2004;129A:105-112.
16. Hershkovitz E, Parvari R, Wudy SA, Hartmann MF, Gomes LG, Loewental N, Miller WL: Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab 2008;93: 3584-3588.
17. Peterson RE, Imperato-McGinley J, Gautier T, Shackleton CH: Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 1985; 313:1182-1191.
18. Malunowicz E, Romer TE, Szarras-Czapnik M, Mielniczuk Z, Gajewska D: Combined deficiency of 17α-hydroxylase and 21-hydroxylase in an 8-year-old girl. Endokrynol Pol 1987;38:117-124.
19. Augarten A, Pariente C, Gazit E, Chayen R, Goldfarb H, Sack J: Ambiguous genitalia due to partial activity of cytochromes P450c17 and P450c21. J Steroid Biochem Mol Biol 1992;41:37-41.
20. Leiberman E, Hershkovitz E, Lauber-Biason A, Phillip M, Zachmann M: Subnormal cortisol response to adrenocorticotropin in isolated partial 17,20-lyase deficiency. J Pediatr Endocrinol Metab 1997;10:387-390.
21. Adachi M, Tachibana K, Asakura Y, Suwa S, Nishimura G: A male patient presenting with major clinical symptoms of glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17α-hydroxylase/17,20-lyase deficiency, but without obvious CYP17 gene mutations. Endocr J 1999;46:285-292.
22. Reardon W, Smith A, Honour JW, Hindmarsh P, Das D, Rumsby G, Nelson I, Malcolm S, Ades L, Sillence D, Kumar D, DeLozier-Blanchet C, McKee S, Kelly T, McKeehan WL, Baraitser M, Winter RM: Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000;37:26-32.
23. Miller WL: Congenital lipoid adrenal hyperplasia: the human gene knockout for the steroidogenic acute regulatory protein. J Mol Endocrinol 1997;19: 227-240.
24. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM: Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003;34:434-439.
25. Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep FC, Claahsen-van der Grinten HL, Arlt W: Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 2009;360:2310-2318.
26. Miller WL: Congenital adrenal hyperplasia. N Engl J Med 1986;314:1321-1322.
27. Shen AL, OLeary KA, Kasper CB: Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPHcytochrome P450 oxidoreductase. J Biol Chem 2002;277:6536-6541.
28. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, Adams RH, Tickle C, Wolf CR: Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003;23:6103-6116.
29. Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K, Miller WL: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228-230.
30. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, Shackleton CH: Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:2128-2135.
31. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A: Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet 2004;128A:333-339.
32. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Fluck CE, Miller WL: Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005:76:729-749.
33. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T, Ogata T: Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005;90:414-426.
34. Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T: Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 2006;59:276-280.
35. Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, Nakacho M, Kowase T, Motomura K, Haruna H, Nakamura M, Ohishi A, Adachi M, Tajima T, Hasegawa Y, Hasegawa T, Horikawa R, Fujieda K, Ogata T: Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 2009;94:1723-1731.
36. Sahakitrungruang T, Huang N, Tee MK, Agrawal V, Russell WE, Crock P, Murphy N, Migeon CJ, Miller WL: Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J Clin Endocrinol Metab 2009;94:4992-5000.
37. Huang N, Agrawal V, Giacomini KM, Miller WL: Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008;105:1733-1738.
38. Pandey AV, Kempna P, Hofer G, Mullis PE, Fluck CE: Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 2007;21:2579-2595.
39. Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, Stewart PM, Arlt W: Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 2007;21:1958-1968.
40. Antley R, Bixler D: Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975;11:397-401.
41. DeLozier CD, Antley RM, Williams R, Green N, Heller RM, Bixler D, Engel E: The syndrome of multisynostotic osteodysgenesis with long-bone fractures. Am J Med Genet 1980;7:391-403.
42. Hassell S, Butler MG: Antley-Bixler syndrome: report of a patient and review of literature. Clin Genet 1994;46:372-376.
43. Crisponi G, Porcu C, Piu ME: Antley-Bixler syndrome: case report and review of the literature. Clin Dysmorphol 1997;6:61-68.
44. Chun K, Siegel-Bartelt J, Chitayat D, Phillips J, Ray PN: FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. Am J Med Genet 1998;77:219-224.
45. Gripp KW, Stolle CA, McDonald-McGinn DM, Markowitz RI, Bartlett SP, Katowitz JA, Muenke M, Zackai EH: Phenotype of the fibroblast growth factor receptor 2 Ser351Cys mutation: Pfeiffer syndrome type III. Am J Med Genet 1998;78:356-360.
46. Pulleyn LJ, Reardon W, Wilkes D, Rutland P, Jones BM, Hayward R, Hall CM, Brueton L, Chun N, Lammer E, Malcolm S, Winter RM: Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet 1996;4:283-291.
47. Schaefer F, Anderson C, Can B, Say B: Novel mutation in the FGFR2 gene at the same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case. Am J Med Genet 1998;75:252-255.
48. Cohen MM Jr: The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 2006;140:2646-2706.
49. Muenke M, Schell U, Hehr A, Robin NH, Losken HW, Schinzel A, Pulleyn LJ, Rutland P, Reardon W, Malcolm S, Winter RM: A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994;8:269-274.
50. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S: Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994;8:98-103.
51. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm S, Winter RM, Oldridge M, Slaney SF, et al: Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 1995;9:173-176.
52. Park WJ, Meyers GA, Li X, Theda C, Day D, Orlow SJ, Jones MC, Jabs EW: Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet 1995;4:1229-1233.
53. Rieckmann T, Zhuang L, Fluck CE, Trueb B: Characterization of the first FGFRL1 mutation identified in a craniosynostosis patient. Biochim Biophys Acta 2009;1792:112-121.
54. Ono T, Bloch K: Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem 1975;250:1571-1579.
55. Debeljak N, Fink M, Rozman D: Many facets of mammalian lanosterol 14β-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch Biochem Biophys 2003;409:159-171.
56. Gofflot F, Hars C, Illien F, Chevy F, Wolf C, Picard JJ, Roux C: Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of hedgehog signaling. Hum Mol Genet 2003;12:1187-1198.
57. Lee GS, Kochhar DM, Collins MD: Retinoidinduced limb malformations. Curr Pharm Des 2004; 10:2657-2699.
58. Schmidt K, Hughes C, Chudek JA, Goodyear SR, Aspden RM, Talbot R, Gundersen TE, Blomhoff R, Henderson C, Wolf CR, Tickle C: Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol Cell Biol 2009;29: 2716-2729.
59. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
60. Lee BE, Feinberg M, Abraham JJ, Murthy AR: Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992;11:1062-1064.
61. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996;22:336-340.
62. Aleck KA, Bartley DL: Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997;72:253-256.
63. Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW: Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 2002;110:95-102.
64. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005;28:1805-1808.
65. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, Ding X: Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278: 25895-25901.
66. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB: Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008;18:11-24.
67. Agrawal V, Huang N, Miller WL: Pharmacogenetics of P450 oxidoreductase. Effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008;18:569-576.
68. Nicolo C, Fluck CE, Mullis PE, Pandey AV: Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol 2010;321:245-252.
69. Pandey AV, Fluck CE, Mullis PE: Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem Biophys Res Commun 2010;400: 374-378.
70. Fluck CE, Mullis PE, Pandey AV: Reduction in hepatic drug metabolising CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun 2010;401:149-153.